查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930032

干癣治疗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2025-2034）

Psoriasis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 166 Pages | 商品交期: 请询问到货日

价格

干癣治疗市场成长因素

预计2025年全球干癣治疗市场规模将达291.5亿美元，2026年成长至314.2亿美元，到2034年将达到729.9亿美元。市场成长的驱动因素包括疾病盛行率上升、生物疗法应用日益广泛、公众意识提升活动不断扩大以及强大的临床研发管线。2025年，北美将以74.83%的市场占有率占据主导地位，这主要得益于生物製剂的高使用率、广泛的保险覆盖率以及强有力的监管审批。

干癣是一种慢性自体免疫发炎性疾病，其特征是皮肤细胞快速增生、斑块形成、发炎、以及干癣性关节炎引起的关节受累。约30-40%的干癣患者会发展为干癣关节炎，增加了长期治疗的需求。斑块型干癣仍然是最常见的类型，占所有病例的80-90%，因此对长期药物治疗的需求持续存在。

市场驱动因素

银屑病患病率的不断上升是主要驱动因素。据估计，全球约有2-3%的人口患有干癣，这推动了对有效全身和局部治疗的需求。各国政府和医疗机构努力促进早期诊断和提高公众对银屑病的认识，提高治疗启动率。

另一个主要驱动因素是针对发炎细胞因子的生物製剂研发管线实力雄厚。 IL-17、IL-23 和 TYK2 抑制剂的监管批准改善了临床疗效，并增强了医生对生物製剂处方的信心。针对儿童和干癣性关节炎患者的适应症扩大，进一步增加了患者的治疗选择。

市场趋势

一个关键趋势是，生物製剂正朝着目标特定免疫路径、安全性和有效性更高的方向发展。与传统疗法相比，生物製剂具有更高的缓解率、更长的缓解持续时间和更低的全身性毒性。製造商大力投资下一代生物製剂和生物相似药，以提高其可负担性和市场准入。

远距皮肤科会诊的引进也改善了病患监测和处方连续性，有助于提高长期用药依从性，尤其是在农村地区和公共卫生紧急情况下。

市场限制因子

高昂的治疗费用仍然是一个重大障碍，尤其是在发展中国家。生物製剂的生产成本高昂，会增加病患的自付费用。有限的偿付限制了低收入者对生物製剂的使用，导致治疗启动延迟和市场渗透率低。

儘管局部用药和全身用药等替代疗法具有成本效益，但它们通常无法提供生物製剂所能提供的长期疾病控制，导致区域间药物可及性差异。

市场区隔分析

依药物类别

市场细分为TNF抑制剂、白血球介素抑制剂和其他药物。预计到2026年，TNF抑制剂将占据市场主导地位，市场占有率达到41.31%，主要得益于其悠久的临床应用历史和生物相似药的普及。然而，由于白细胞介素抑制剂具有卓越的疗效、更高的安全性以及不断扩大的临床试验计画，因此预计其成长速度将最快。

依类型划分

依类型划分，市场包括斑块状干癣、干癣关节炎和其他疾病。2026年，斑块状干癣将占市场占有率的41.31%，这主要得益于其高发病率和庞大的患者群体。银屑病关节炎市场正经历快速成长，这主要归功于诊断率的提高和生物製剂的广泛应用。

依产品类型划分

依产品类型划分，市场分为生物製剂和非生物製剂。2026年，生物製剂将占市场占有率的90.73%，这充分反映了IL-17和IL-23抑制剂等标靶疗法的广泛应用。由于口服药物的核准以及其低成本带来的高可及性，非生物製剂市场持续成长。

依给药途径

市场分为口服、肠外/全身给药及局部给药。2026年，肠外/全身给药占83.48%的市场占有率，这主要得益于生物製剂注射和输注给药的广泛应用。口服给药因其便利性和TYK2抑制剂获批数量的增加而不断扩大。

依通路

通路包括医院药房、零售药房和线上药房。2024年，零售药局凭藉其广泛的覆盖范围和便利的处方续药服务占据主导地位，而线上药局则透过送货上门服务和生物相似药合作迅速扩张。

区域展望

2025年，北美市场规模达到218.1亿美元，主要得益于先进生物製剂的引进及完善的医保偿付系统。受FDA批准和联邦医疗保险（Medicare）价格谈判的推动，美国市场预计到2026年将达到217.5亿美元。

欧洲市场需求强劲，预计到2026年，德国市场规模将达到10.5亿美元，英国将达到6.3亿美元，这主要得益于监管部门的批准和完善的医疗保险体系。亚太地区是成长最快的地区，预计到2026年，中国市场规模将达到7.4亿美元，日本将达到6.1亿美元，印度将达到2.7亿美元，这主要得益于临床试验的扩展和政府的宣传推广活动。拉丁美洲和中东及非洲地区正透过扩大医疗保健服务覆盖范围和提高疾病认知度而实现成长。

本报告分析了2025年、2026年和2034年的市场规模和价值，并依药物类别、类型、产品类型、给药途径和通路进行了细分。报告还包括区域和国家特定的市场价值、监管动态、产品上市、临床研发管线进展以及影响全球银屑病治疗行业的竞争策略。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 2025年主要全国干癣率
  • 主要国家/地区监管和偿付状况概述
  • 主要公司新产品发布
  • 主要公司产品线分析
  • 主要公司主要产业趋势
  • 新冠疫情对市场的影响

章节5：全球干癣治疗市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测 - 依药物类别划分
    • TNF抑制剂
    • 白血球介素抑制剂
    • 其他
  • 市场分析、洞察与预测 - 依类型划分
    • 斑块状干癣
    • 干癣关节炎
    • 其他
  • 市场分析、洞察与预测 - 依产品类型划分
    • 生物製品
    • 非生物製品
  • 市场分析、洞察与预测 - 依给药途径划分
    • 口服
    • 注射/全身给药
    • 外用
  • 市场分析、洞察与预测 - 依通路划分通路
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美干癣治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲干癣治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第8章 亚太地区干癣治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲和纽西兰
    • 亚太其他地区

第9章 拉丁美洲干癣治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家国家/地区

第10章 中东和非洲干癣治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • GCC
    • 南非
    • 其他中东和非洲国家/地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • AbbVie Inc.
    • Novartis AG
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
    • LEO Pharma A/S
    • Merck &Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Evelo Biosciences, Inc.
    • UCB S.A.
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI100600

Growth Factors of psoriasis treatment Market

The global psoriasis treatment market size was valued at USD 29.15 billion in 2025 and is projected to grow to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034. Market growth is supported by rising disease prevalence, increasing adoption of biologic therapies, expanding awareness programs, and strong clinical development pipelines. In 2025, North America dominated the market with a share of 74.83%, driven by high biologic usage, extensive insurance coverage, and robust regulatory approvals.

Psoriasis is a chronic autoimmune inflammatory disorder characterized by rapid skin cell proliferation, plaque formation, inflammation, and joint involvement in psoriatic arthritis. Approximately 30%-40% of psoriasis patients develop psoriatic arthritis, increasing long-term therapy needs. Plaque psoriasis remains the most common form, accounting for 80%-90% of total cases, creating sustained demand for long-term pharmacologic management.

Market Drivers

The growing prevalence of psoriasis remains a primary driver. An estimated 2%-3% of the global population suffers from psoriasis, increasing demand for effective systemic and topical therapies. Governments and healthcare organizations are promoting early diagnosis and disease awareness, improving treatment initiation rates.

Another major driver is the strong pipeline of biologic drugs targeting inflammatory cytokines. Regulatory approvals for IL-17, IL-23, and TYK2 inhibitors are improving clinical outcomes and increasing physician confidence in biologic prescribing. Expanded indications for pediatric and psoriatic arthritis populations further increase patient eligibility.

Market Trends

A dominant trend is the shift toward biologic therapies that target specific immune pathways with improved safety and efficacy. Biologics offer higher clearance rates, longer remission periods, and reduced systemic toxicity compared to conventional therapies. Manufacturers are investing heavily in next-generation biologics and biosimilars to improve affordability and expand market access.

Teledermatology adoption is also improving patient monitoring and prescription continuity, particularly in rural regions and during public health emergencies, supporting long-term medication adherence.

Market Restraints

High treatment costs remain a significant barrier, especially in developing countries. Biologic therapies involve high manufacturing expenses, leading to elevated out-of-pocket costs for patients. Limited reimbursement frameworks restrict biologic adoption in low-income populations, delaying therapy initiation and reducing market penetration.

Topical and systemic alternatives remain cost-effective but often lack the long-term disease control achieved by biologics, creating access disparities across regions.

Segmentation Analysis

By Drug Class

The market is segmented into TNF inhibitors, interleukin inhibitors, and others. TNF inhibitors dominated with 41.31% market share in 2026, driven by long-established clinical usage and biosimilar availability. However, interleukin inhibitors are registering the fastest growth due to superior efficacy, improved safety profiles, and expanding clinical trial programs.

By Type

By type, the market includes plaque psoriasis, psoriatic arthritis, and others. Plaque psoriasis accounted for 41.31% market share in 2026, driven by high disease prevalence and large patient populations. Psoriatic arthritis is experiencing rapid growth due to improved diagnostic rates and expanded biologic indications.

By Product Type

Based on product type, the market is segmented into biologics and non-biologics. Biologics dominated with 90.73% share in 2026, reflecting strong adoption of targeted therapies such as IL-17 and IL-23 inhibitors. Non-biologics continue to grow due to oral drug approvals and lower cost accessibility.

By Route of Administration

The market is categorized into oral, parenteral/systemic, and topical. Parenteral/systemic therapies accounted for 83.48% share in 2026, supported by widespread biologic administration through injections and infusions. Oral therapies are expanding due to convenience and increasing TYK2 inhibitor approvals.

By Distribution Channel

Distribution includes hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominated in 2024 due to wide accessibility and refill convenience, while online pharmacies are expanding rapidly through home delivery services and biosimilar partnerships.

Regional Outlook

North America generated USD 21.81 billion in 2025, supported by advanced biologic adoption and strong reimbursement systems. The U.S. market reached USD 21.75 billion in 2026, driven by FDA approvals and Medicare pricing negotiations.

Europe holds strong demand, with Germany valued at USD 1.05 billion and the U.K. at USD 0.63 billion in 2026, supported by regulatory approvals and national healthcare coverage. Asia Pacific is the fastest-growing region, with China at USD 0.74 billion, Japan at USD 0.61 billion, and India at USD 0.27 billion in 2026, driven by clinical trial expansion and government awareness programs. Latin America and Middle East & Africa are growing through expanding healthcare access and disease awareness.

Competitive Landscape

Key players include AbbVie, Johnson & Johnson, Novartis, Pfizer, Eli Lilly, Amgen, LEO Pharma, UCB, and Sun Pharmaceutical Industries. Market leaders focus on biologic innovation, biosimilar expansion, and multi-indication labeling strategies. Strategic acquisitions and global clinical programs strengthen product pipelines and market coverage.

Report Coverage

The report analyzes market size and value for 2025, 2026, and 2034, with segmentation by drug class, type, product type, route of administration, and distribution channel. It includes regional and country-level market values, regulatory trends, product launches, clinical pipeline developments, and competitive strategies shaping the global psoriasis treatment industry.

Conclusion

The psoriasis treatment market is expanding from USD 29.15 billion in 2025 to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034, driven by rising disease burden, biologic therapy innovation, and expanding global treatment access. Dominance of biologics, strong performance of parenteral therapies, and leadership by North America reflect advanced treatment adoption, while rapid growth in Asia Pacific highlights increasing healthcare investment and regulatory support. Continued innovation in immune-targeted therapies, biosimilars, and oral treatment options is strengthening long-term market sustainability across diverse patient populations.

Segmentation By Drug Class

  • TNF Inhibitors
  • Interleukins Inhibitors
  • Others

By Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

By Product Type

  • Biologics
  • Non-Biologics

By Route of Administration

  • Oral
  • Parenteral/Systemic
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country)
    • U.S. (By Type)
    • Canada (By Type)
  • Europe (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K. (By Type)
    • Germany (By Type)
    • France (By Type)
    • Italy (By Type)
    • Spain (By Type)
    • Scandinavia (By Type)
    • Rest of Europe (By Type)
  • Asia Pacific (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan (By Type)
    • China (By Type)
    • India (By Type)
    • Australia & New Zealand (By Type)
    • Rest of Asia Pacific (By Type)
  • Latin America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil (By Type)
    • Mexico (By Type)
    • Rest of Latin America (By Type)
  • Middle East & Africa (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC (By Type)
    • South Africa (By Type)
    • Rest of the Middle East & Africa (By Type)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Psoriasis, By Key Countries, 2025
  • 4.2. Overview: Regulatory Scenario & Reimbursement Scenario, By Key Countries/Region
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. TNF Inhibitors
    • 5.1.2. Interleukins Inhibitors
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Plaque Psoriasis
    • 5.2.2. Psoriatic Arthritis
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Product Type
    • 5.3.1. Biologics
    • 5.3.2. Non-Biologics
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Parenteral/Systemic
    • 5.4.3. Topical
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. TNF Inhibitors
    • 6.1.2. Interleukins Inhibitors
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Plaque Psoriasis
    • 6.2.2. Psoriatic Arthritis
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Product Type
    • 6.3.1. Biologics
    • 6.3.2. Non-Biologics
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Parenteral/Systemic
    • 6.4.3. Topical
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
      • 6.6.1.1. By Type
    • 6.6.2. Canada
      • 6.6.2.1. By Type

7. Europe Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. TNF Inhibitors
    • 7.1.2. Interleukins Inhibitors
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Plaque Psoriasis
    • 7.2.2. Psoriatic Arthritis
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Product Type
    • 7.3.1. Biologics
    • 7.3.2. Non-Biologics
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Parenteral/Systemic
    • 7.4.3. Topical
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K
      • 7.6.1.1. By Type
    • 7.6.2. Germany
      • 7.6.2.1. By Type
    • 7.6.3. France
      • 7.6.3.1. By Type
    • 7.6.4. Spain
      • 7.6.4.1. By Type
    • 7.6.5. Italy
      • 7.6.5.1. By Type
    • 7.6.6. Scandinavia
      • 7.6.6.1. By Type
    • 7.6.7. Rest of Europe
      • 7.6.7.1. By Type

8. Asia Pacific Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. TNF Inhibitors
    • 8.1.2. Interleukins Inhibitors
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Plaque Psoriasis
    • 8.2.2. Psoriatic Arthritis
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Product Type
    • 8.3.1. Biologics
    • 8.3.2. Non-Biologics
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Parenteral/Systemic
    • 8.4.3. Topical
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
      • 8.6.1.1. By Type
    • 8.6.2. China
      • 8.6.2.1. By Type
    • 8.6.3. India
      • 8.6.3.1. By Type
    • 8.6.4. Australia & New Zealand
      • 8.6.4.1. By Type
    • 8.6.5. Rest of Asia Pacific
      • 8.6.5.1. By Type

9. Latin America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. TNF Inhibitors
    • 9.1.2. Interleukins Inhibitors
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Plaque Psoriasis
    • 9.2.2. Psoriatic Arthritis
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Product Type
    • 9.3.1. Biologics
    • 9.3.2. Non-Biologics
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Parenteral/Systemic
    • 9.4.3. Topical
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
      • 9.6.1.1. By Type
    • 9.6.2. Mexico
      • 9.6.2.1. By Type
    • 9.6.3. Rest of Latin America
      • 9.6.3.1. By Type

10. Middle East & Africa Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. TNF Inhibitors
    • 10.1.2. Interleukins Inhibitors
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Plaque Psoriasis
    • 10.2.2. Psoriatic Arthritis
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Product Type
    • 10.3.1. Biologics
    • 10.3.2. Non-Biologics
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Parenteral/Systemic
    • 10.4.3. Topical
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
      • 10.6.1.1. By Type
    • 10.6.2. South Africa
      • 10.6.2.1. By Type
    • 10.6.3. Rest of Middle East & Africa
      • 10.6.3.1. By Type

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Novartis AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. LEO Pharma A/S
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Amgen Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Eli Lilly and Company
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Evelo Biosciences, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. UCB S.A.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Sun Pharmaceutical Industries Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 3: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 4: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Canada Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 15: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Germany Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: France Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 24: Italy Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 25: Spain Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Scandinavia Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Rest of Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 29: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 31: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 32: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 33: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 35: India Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 36: Japan Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Australia & New Zealand Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 38: Rest of Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 39: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 40: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 41: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 42: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 43: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 44: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 45: Brazil Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 46: Mexico Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 47: Rest of Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 48: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 49: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 50: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 51: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 52: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 53: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 54: GCC Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 55: South Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 56: Rest of Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034

List of Figures

  • Figure 1: Global Psoriasis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Psoriasis Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Psoriasis Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Psoriasis Treatment Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 5: Global Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Psoriasis Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 11: North America Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 12: North America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 13: North America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 14: North America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Psoriasis Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Psoriasis Treatment Market Value Share (%), By Country, 2025
  • Figure 20: Europe Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Europe Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 24: Europe Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 25: Europe Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 26: Europe Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 35: Asia Pacific Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 36: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 37: Asia Pacific Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 38: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 47: Latin America Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 48: Latin America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 49: Latin America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 50: Latin America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 59: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 60: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 61: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 62: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Psoriasis Treatment Market Share (%), By Company, 2025